Dornase alfa

Drug Profile

Dornase alfa

Alternative Names: DNase; Dornase alpha; dornase-alpha; Pulmozyme; Recombinant human deoxyribonuclease I; rhDNase

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Genentech
  • Developer Chugai Pharmaceutical; Genentech; University of Illinois at Chicago
  • Class Recombinant proteins
  • Mechanism of Action Deoxyribonuclease 1 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Cystic fibrosis
  • Phase I/II Dry eyes
  • Discontinued Chronic obstructive pulmonary disease; Lupus nephritis

Most Recent Events

  • 01 Apr 2016 The University of Illinois, in collaboration with Genentech and National Eye Institute initiate a phase-I/II clinical trial in Dry eyes in USA (Intraocular) (NCT02702518)
  • 01 Jul 2014 Phase-I/II clinical trials in Dry eyes in USA (Intraocular) (NCT02193490)
  • 08 Jun 2012 Launched for Cystic fibrosis in Belgium (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top